Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SENTINEO: MagTrace and Magseed for Axillary Node Identification
NCT05625698Completed
- Sponsor
- Region Västra Götaland
- Start
- Oct 2021
- Primary completion
- Oct 2023
- Modality
- Nanoparticles
- Countries
- 1
01
Overview
Open-label trial of Magtrace in breast cancer, sponsored by Region Västra Götaland. Primary endpoint: Detection rate of axillary sentinel node after neoadjuvant chemotherapy. Started Oct 2021; status: completed.
02
Drugs
Magtrace
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05625698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05625698.